Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TD Vaccine System
- Development stage
- Phase 3
- Lead developer
- Vivalis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
The TD Vaccine System is a vaccine developed by Intercell USA, Inc. for the prevention of moderate to severe enterotoxigenic E. coli (ETEC) disease. This vaccine system contains the heat labile enterotoxin (LT) of E. coli, which acts as an antigen to stimulate an immune response. Intercell USA, Inc. was known for its work on transcutaneous immunization (TCI) and vaccine patch delivery systems, suggesting a transdermal route of administration for this vaccine. It is being evaluated for use in travelers to regions such as India.
- Other names
- Travelers' Diarrhea Vaccine Systemtravelers diarrhea vaccine patch
02
Targets
GD1a (Disialoganglioside GD1a)
Beyond the preview
Go deeper on TD Vaccine System.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TD Vaccine System.